Oncostatin M and Nivolumab Affect the Cytotoxic T-Cell Proportions and the Susceptibility to TRAIL-Induced Death in Non-Leukocyte Cell Subpopulations in Soft Tissue Sarcomas
Language English Country Switzerland Media print-electronic
Document type Journal Article
PubMed
36996792
DOI
10.1159/000529811
PII: 000529811
Knihovny.cz E-resources
- Keywords
- Cytokines, Monoclonal antibody, Nivolumab, Oncostatin M, Soft tissue sarcomas, T cells, Tumor microenvironment,
- MeSH
- Cohort Studies MeSH
- Leiomyosarcoma * MeSH
- Humans MeSH
- Liposarcoma * MeSH
- Tumor Microenvironment MeSH
- Nivolumab pharmacology therapeutic use MeSH
- Oncostatin M pharmacology metabolism MeSH
- T-Lymphocytes metabolism MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Nivolumab MeSH
- Oncostatin M MeSH
INTRODUCTION: Soft tissue sarcomas (STSs) are malignant tumors arising from mesenchymal tissues. Patients with advanced and metastatic STSs have low overall survival rates and relatively limited treatment options. Oncostatin M (OSM) is a pleiotropic cytokine that was shown to carry both pro- and anti-tumorigenic properties in various cancer types. However, the role of OSM in STSs has not yet been elucidated. Moreover, the potential additive effects of combining OSM and anti-PD-1 therapy have not been carried out so far. METHODS: The aim of this study was to determine the effects of in vitro OSM administration on liposarcoma, leiomyosarcoma, and myxofibrosarcoma immune cells isolated from peripheral blood and tumor tissues and the potential cooperative nature of OSM and nivolumab in treating these STSs. We designed a cohort study to explore novel histology-driven therapies in our target STSs. The immune cells were isolated from the peripheral blood and tumors of patients with STS, and the proportions and phenotypes of immune cells were evaluated with flow cytometry after cultivation with therapeutic monoclonal antibodies. RESULTS: The proportion of peripheral CD45+ cells was not affected by OSM but was significantly increased by nivolumab, whereas both treatments had an effect on CD8+ T cells. In tumor tissues, CD8+ T cell and CD45‒ TRAIL+ cell cultures were boosted by nivolumab and significantly enriched by OSM. Our data suggest that OSM may play a role in the treatment of leiomyosarcoma, myxofibrosarcoma, and liposarcoma. CONCLUSION: In conclusion, the biological efficacy of OSM is reflected in the tumor microenvironment rather than in the peripheral blood of the patients in our cohort, and nivolumab could potentiate its mechanism of action in selected cases. Nevertheless, more histotype-tailored studies are needed to fully understand the functions of OSM in STSs.
Department of Methodology Faculty of Physical Education and Sport Charles University Prague Czechia
Department of Surgery Oncology and Gastroenterology University of Padova Padova Italy
References provided by Crossref.org